Figure 5. FGTI-2734 inhibits oncogenic pathways mediated by AKT, mTOR, and cMYC, upregulates the tumor suppressor p53, and activates CASPASE 3 in patient-derived xenografts in vivo.

Tumor tissue lysates from 6 vehicle-treated (mouse 1–6) and 7 FGTI-2734-treated (100mg/kg body weight; mouse 7–13) mice from patient 2 PDX were processed for Western blot analysis with indicated antibodies. A, Western blot results; superscripts a-e shown by antibodies correspond to loading controls containing vinculin or β-ACTIN. B and C, Quantification of Western blot results; letters a-f indicate statistical significance (P<0.05).